+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression



Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression



Human Gene Therapy 4(2): 143-150



Transgenic mice have been generated to determine the tissue-specific expression, safety, and efficacy of a novel chimeric gene that is being investigated as a test system for virus-directed enzyme prodrug therapy (VDEPT). The chimeric gene consists of the transcriptional regulatory sequences of the albumin gene and the protein-coding sequence of the varicella-zoster virus thymidine kinase (VZV-TK) gene inserted into a retroviral vector. Eight founders were obtained from microinjection of a nearly full-length proviral fragment containing the chimeric gene. Liver extracts of the founders and 12 G1 mice were analyzed by enzymatic and Western blot analysis for the presence of VZV-TK. No VZV-TK enzymatic activity or protein was detected. Methylation analysis indicated that both the chimeric gene and retroviral sequences were methylated. Treatment of newborn mice with 5-azacytidine or backcrossing into a DBA/2 genetic background did not result in detectable VZV-TK expression or a change in transgene methylation. The poor transgene expression reported here appears to reflect an inherent, continuing problem of transgenic technology with transgenes that are essentially intact retroviral shuttle vectors. These methylation and expression problems are generally applicable to other animal models for retroviral-mediated gene therapy and should be of interest to researchers as they design and evaluate preclinical safety and efficacy studies.

(PDF emailed within 0-6 h: $19.90)

Accession: 002390000

Download citation: RISBibTeXText

PMID: 8388259

DOI: 10.1089/hum.1993.4.2-143


Related references

Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. Biochemical and Biophysical Research Communications 287(4): 1034-1040, 2001

Retroviral mediated gene therapy for hepatocellular carcinoma a transgenic mouse model. Proceedings of the American Association for Cancer Research Annual Meeting 32: 299, 1991

Retrovirus-mediated gene therapy for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhance directly linked to its promoter. Cancer Gene Therapy 5(5): 301-306, 1998

Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. Journal of Virology 71(12): 9163-9169, 1997

Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice. International Journal of Molecular Medicine 1(4): 671-675, 1998

IgH enhancer-mediated deregulation of N-myc gene expression in transgenic mice: generation of lymphoid neoplasias that lack c-myc expression. Embo Journal 8(4): 1121-1128, 1989

Expression and antitumor activity of retrovirus-mediated tumor necrosis factor alpha gene in human hepatocellular carcinoma cells. Zhonghua Weishengwuxue He Mianyixue Zazhi 16(1): 33-36, 1996

TCR transgenic analysis of class I and II restricted tumour-vaccinia asa cytokine gene therapy vector in cancer Persistent transgene expression despite antibody generation. FASEB Journal 13(4 PART 1): A300, March 12, 1999

Bicistronic DNA construct comprising X-myc transgene for use in production of transgenic animal model systems for human hepatocellular carcinoma and transgenic animal model systems so produced. Official Gazette of the United States Patent & Trademark Office Patents 1249(2), Aug 14, 2001

Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Research 55(22): 5283-5287, 1995

Amelioration of retrovirus-mediated gene transfer into hepatocellular carcinoma cells. International Journal of Oncology 18(4): 801-807, 2001

Expression of swine MHC class II genes in a cynomolgus monkey: Retrovirus-mediated gene therapy in a preclinical transplantation model. Xenotransplantation 4(3): 174-185, 1997

Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Research 61(3): 1005-1012, 2001

Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology 34(1): 72-81, 2001